Open dialogue is an important part of the drug approval process. Physicians, patients and advocates want transparent discussion about new therapies — their benefits, their
If health plans heed a new report from the Institute for Clinical and Economic Review, patients with few options to treat their cystic fibrosis may
By Tammy Dodderidge, International Essential Tremor Foundation Is she nervous? Is she cold? Maybe she drank too much coffee. Could she be going through withdrawal?
The risk of death may be lower for certain patients taking cholesterol-lowering PCSK9 inhibitors, new research shows. But how many patients will actually be able
Health plans said “no” to one in every four Americans whose doctor prescribed a cholesterol-lowering PCSK9 inhibitor in 2017. And that, according to the Institute
There was a lot of head nodding at the inaugural meeting of the Alliance for Patient Access’ Diabetes Therapy Access Working Group. Especially when the
by Brian Kennedy, Executive Director, Alliance for Patient Access Declaring equal rights is a noble gesture. But history teaches us that it is just the first